National Biomedical Research Act

S 5637 establishes the Biomedical Innovation Fund in the Treasury, requiring annual $10 billion transfers from the general fund starting September 1, 2025, through 2034. The fund distributes amounts to the National Institutes of Health (NIH) and Food and Drug Administration (FDA) based on their discretionary appropriations relative to minimum funding levels, with 20% of each annual allocation available for obligation each year over five fiscal years. Funds must support specific research activities including basic disease research, innovative treatments for unmet medical needs, early-career scientist programs, and studies targeting conditions disproportionately affecting Medicare/Medicaid populations. The bill strictly prohibits non-compliant uses and mandates annual reports on fund operations and research outcomes to Congress.